HIV (human immunodeficiency virus) is a virus that attacks the body's immune system. If HIV is not treated, it can lead to AIDS (acquired immunodeficiency syndrome). Learning the basics about HIV can keep you healthy and prevent HIV transmission. You can also download sharing materials or watch videos on basic HIV information.

This may be an argument in favor of the use of dolutegravir-based regimens in cases where it is difficult to maintain high levels of adherence or there is an increased risk of treatment interruptions.

A French study, the results of which have been published in the Open Forum Infectious Diseases journal, revealed that people taking antiretroviral regimens based on the integrase inhibitor dolutegravir (Tivicay®; also in Juluca®, Dovato® and Triumeq®) had more likely to achieve sustained viral suppression, even in situations of lower adherence and treatment interruptions, compared to older antiretroviral drug-based regimens (ie, non-nucleoside reverse transcriptase inhibitors [NNRTIs], inhibitors of boosted protease [PI] and even first-generation integrase inhibitors such as raltegravir).

Treatment options for HIV have progressed and improved over time, and today a large proportion of infected people limit their treatment to a single daily tablet.

This type of analysis makes it possible to estimate the expected incidence of HIV in the event that a placebo control group had been included in a trial

The use of cabotegravir as pre-exposure prophylaxis (PrEP) against HIV administered in injections every two months would be highly effective in women. This effectiveness could be even greater than suggested in previous analyzes. This is the main conclusion of a study whose results were announced at the XI Conference of the International AIDS Society on the Science of HIV (IAS 2021), held last week virtually due to the COVID-19 pandemic

Long-acting injectable cabotegravir (Vocabria®) is a new integrase inhibitor that has been licensed as a treatment for HIV infection and is administered monthly or bi-monthly together with long-acting injectable rilpivirine (Rekambys®). Cabotegravir has also been developed for the prevention of HIV although its use as PrEP has not yet been licensed.

Results from different trials reveal that people with HIV who meet both criteria could potentially benefit from proof-of-concept trials in the cure of HIV

According to three studies presented this week at the 11th International AIDS Society Conference on HIV Science (IAS 2021), which is being held virtually due to the COVID-19 pandemic, people with HIV who initiate the antiretroviral treatment (ART) early and before far-reaching damage to the immune system would have smaller reservoirs of HIV.

HIV infection is inherently incurable with antiretroviral treatment because, although it is possible to completely stop the replication of the virus for long periods, if the treatment is stopped, the replication restarts at the expense of the viral reservoirs on which the drugs cannot act. antiretrovirals.